% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gwenzi:276329,
      author       = {T. Gwenzi$^*$ and A. Zhu$^*$ and P. Schrotz-King$^*$ and B.
                      Schöttker$^*$ and M. Hoffmeister$^*$ and H. Brenner$^*$},
      title        = {{E}ffects of vitamin {D} supplementation on inflammatory
                      response in patients with cancer and precancerous lesions:
                      {S}ystematic review and meta-analysis of randomized trials.},
      journal      = {Clinical nutrition},
      volume       = {42},
      number       = {7},
      issn         = {0261-5614},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-01059},
      pages        = {1142-1150},
      year         = {2023},
      note         = {2023 Jul;42(7):1142-1150 / #EA:C120#LA:C120#LA:C070#},
      abstract     = {Inflammation plays a key role in tumor development and
                      progression. Vitamin D has potential tumor suppressing
                      effects through modulation of inflammatory processes. The
                      aim of this systematic review and meta-analysis of
                      randomized controlled trials (RCTs) was to summarize and
                      evaluate the effects of vitamin D3 supplementation (VID3S)
                      on serum inflammatory biomarkers among patients with cancer
                      or pre-cancerous lesions.We searched PubMed, Web of Science
                      and Cochrane databases until November 2022. The effects of
                      VID3S were estimated from pooled standardized mean
                      differences (SMDs) with their $95\%$ confidence intervals
                      (CIs) for inflammatory biomarker follow-up levels between
                      intervention and control groups.Meta-analysis of eight RCTs
                      (total of 592 patients with cancer or pre-cancerous
                      conditions) showed that VID3S significantly lowered levels
                      of serum tumor necrosis factor (TNF)-α (SMD $[95\%CI]:$
                      -1.65 [-3.07; -0.24]). VID3S also resulted in statistically
                      non-significantly lower serum levels of interleukin (IL)-6
                      (SMD $[95\%CI]:$ -0.83, [-1.78; 0.13]) and C-reactive
                      protein (CRP) (SMD $[95\%CI]:$ -0.09, [-0.35; 0.16]),
                      whereas IL-10 levels were unaltered (SMD $[95\%CI]:$ -0.00,
                      [-0.50; 0.49]).Our study shows evidence of a significant
                      reduction of TNF-α levels by VID3S for patients with cancer
                      or precancerous lesions. Patients with cancer or
                      precancerous lesions may benefit from personalized VID3S in
                      suppressing tumour-promoting inflammatory
                      response.CRD42022295694.},
      keywords     = {Biomarker (Other) / Cancer (Other) / Inflammation (Other) /
                      Precancer (Other) / Vitamin D3 supplement (Other)},
      cin          = {C120 / C070 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)C120-20160331 / I:(DE-He78)C070-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37244755},
      doi          = {10.1016/j.clnu.2023.05.009},
      url          = {https://inrepo02.dkfz.de/record/276329},
}